Reiji Muto

Reiji Muto

Auto-generated profile, based on publicly available information

Reiji Muto


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 October 2018 in Cancer Medicine
Verified
Journal Article
Open access
PDF file
RMReiji Muto
Reiji Muto
HMHiroaki Miyoshi
Hiroaki Miyoshi
KSKensaku Sato
Kensaku Sato
TFTakuya Furuta
Takuya Furuta
HMHiroko Muta
Hiroko Muta
KOKoichi Ohshima
Koichi Ohshima
This study provides an overview of the epidemiology and secular trends of malignant lymphoma in Japan. Using data from clinics and hospitals throughout Japan, we analyzed 9426 cases of malignant lymphoma diagnosed in 2007‐2014. We show that the proportion of follicular lymphoma and methotrexate‐associated lymphoproliferative disorder increased during this time, as did the onset age for follicular lymphoma and diffuse large B‐cell lymphoma. Significant increases in onset age for follicular lymphoma and diffuse large B‐cell lymphoma were observed in both men and women (all P values <0.0001 except for P = 0.0448 for the latter disease in women). Further studies are required to determine the reasons for the higher proportion of and onset age for these lymphomas. Additionally, we believe that continued observation of these trends is necessary.

17 August 2021 in British Journal of Haematology
Verified
Journal Article
Open access
PDF file
YSYuma Sakamoto
Yuma Sakamoto
TITakashi Ishida
Takashi Ishida
AMAyako Masaki
Ayako Masaki
TMTakayuki Murase
Takayuki Murase
MTMorishige Takeshita
Morishige Takeshita
HIHiroshi Inagaki
Hiroshi Inagaki
Summary: Adult T‐cell leukaemia/lymphoma (ATL) patients have a poor prognosis. Here, we investigated the impact of TP53 gene mutations on prognosis of ATL treated in different ways. Among 177 patients, we identified 47 single nucleotide variants or insertion‐deletions (SNVs/indels) of the TP53 gene in 37 individuals. TP53 copy number variations (CNVs) were observed in 38 patients. Altogether, 67 of 177 patients harboured TP53 SNVs/indels or TP53 CNVs, and were categorized as having TP53 mutations. In the entire cohort, median survival of patients with and without TP53 mutations was 1·0 and 6·7 years respectively (P < 0·001). After allogeneic haematopoietic stem cell transplantation (HSCT), median survival of patients with (n = 16) and without (n = 29) TP53 mutations was 0·4 years and not reached respectively (P = 0·001). For patients receiving mogamulizumab without allogeneic HSCT, the median survival from the first dose of antibody in patients with TP53 mutations (n = 27) was only 0·9 years, but 5·1 years in those without (n = 42; P < 0·001). Thus, TP53 mutations are associated with unfavourable prognosis of ATL, regardless of treatment strategy. The establishment of alternative modalities to overcome the adverse impact of TP53 mutations in patients with ATL is required.

20 March 2024 in Cancer Medicine
Verified
Journal Article
Open access
RMReiji Muto
Reiji Muto
HMHiroaki Miyoshi
Hiroaki Miyoshi
KNKazutaka Nakashima
Kazutaka Nakashima
MTMai Takeuchi
Mai Takeuchi
MHMakoto Hamasaki
Makoto Hamasaki
KOKoichi Ohshima
Koichi Ohshima
Aims: T‐follicular helper (TFH) cells are effector T‐cells that are crucial for B‐cell selection and differentiation. T‐cell lymphomas derived from TFH cells have distinct characteristics. Additionally, in the World Health Organization (WHO) classification 5th edition, three lymphomas were introduced as independent disease entities with TFH cell origin. We aimed to investigate the clinicopathological features of adult T‐cell leukemia/lymphoma (ATLL) with a TFH phenotype (TFHP).Methods and Results: We performed TFH immunohistochemistry analysis of five biomarkers for the biopsy specimen, with TFHP being indicated by a positive result for more than two markers. Among 75 cases of ATLL, 37.3% of them showed TFHP. Compared with cases of ATLL without TFHP, cases of ATLL with TFHP showed higher C‐reactive protein levels (p = 0.0219) and increased high endothelial venule proliferation (p = 0.024). However, there were no significant between‐group differences in overall survival as well as other clinical and morphological findings. Furthermore, there was no significant between‐group difference in TFH markers and FOXP3 expression.Conclusion: Some patients with ATLL may present a TFHP, which should not preclude the diagnosis of ATLL. Although presenting a TFHP does not affect prognosis, it is important to identify cases of ATLL with a TFHP since it may inform future treatment strategies.

6 September 2022 in Hematological Oncology
Verified
Journal Article
Open access
YSYuma Sakamoto
Yuma Sakamoto
TITakashi Ishida
Takashi Ishida
AMAyako Masaki
Ayako Masaki
TMTakayuki Murase
Takayuki Murase
EOEiichi Ohtsuka
Eiichi Ohtsuka
HIHiroshi Inagaki
Hiroshi Inagaki
Adult T-cell leukemia/lymphoma (ATL) patients have a very poor prognosis. The humanized anti-CCR4 therapeutic monoclonal antibody, mogamulizumab, is a key agent for ATL treatment. Our previous integrated molecular analysis demonstrated that among all the driver genes in ATL, CCR7 gene alterations were significantly associated with clinical response to mogamulizumab. Accordingly, here we investigated the detailed clinical impact of CCR7 alterations in a larger cohort of ATL patients. These CCR7 alterations, most of which lead to C-terminus truncations, were observed in 27 of 223 patients (12%). For patients receiving mogamulizumab but not allogeneic hematopoietic stem cell transplantation (HSCT), CCR7 alterations were significantly associated with worse survival (median survival from the first dose of mogamulizumab of 0.7 years for 12 patients with CCR7 alterations vs. 1.6 years for 72 patients without, p = 0.020). On the other hand, the presence or absence of CCR7 alterations had no significant impact on survival in the entire cohort (median overall survival of 1.4 and 1.8 years, respectively, p = 0.901), or on the survival of patients receiving allogeneic HSCT (median survival from the day of transplantation of 0.9 years for 6 patients with CCR7 alterations and 1.4 years for 48 without, p = 0.543). Multivariate analysis indicated that patients with CCR4 alterations but lacking CCR7 alterations (n = 20) had significantly better survival after receiving mogamulizumab-containing treatments (hazard ratio for survival, 0.437, 95% confidence interval, 0.192-0.994). This study contributes to the establishment of precision medicine for ATL.

3 December 2018 in Neuropathology
Verified
Journal Article
Closed access
PDF file
RMReiji Muto
Reiji Muto
YSYasuo Sugita
Yasuo Sugita
SMSeiya Momosaki
Seiya Momosaki
YIYuriko Ito
Yuriko Ito
YWYoshiyuki Wakugawa
Yoshiyuki Wakugawa
KOKoichi Ohshima
Koichi Ohshima

13 October 2020 in Pathology International
Verified
Journal Article
Closed access
PDF file
RMReiji Muto
Reiji Muto
NUNaoki Uemura
Naoki Uemura
NMNorikazu Mitsui
Norikazu Mitsui
FAFumiko Arakawa
Fumiko Arakawa
TNTakanori Negishi
Takanori Negishi
TMToshihiko Murayama
Toshihiko Murayama